Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-079 in Relapsed/Refractory Multiple Myeloma
NCT03439280Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Apr 2018
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of mezagitamab in multiple myeloma (MM), sponsored by Millennium Pharmaceuticals. Started Apr 2018; status: completed.
02
Drugs
mezagitamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03439280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03439280.